Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

146644 Press Releases
DateTitleCompany
04 Dec 16 Nordic Nanovector: Single-dose Betalutin® Shows Promising Efficacy, Improved Duration of Response and Favourable Safety in Relapsed NHL Patients Nordic Nanovector,
Published by
Business Wire
04 Dec 16 Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL Published by
GlobeNewswire
04 Dec 16 Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL Novartis International AG,
Published by
GlobeNewswire
04 Dec 16 In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia The Children's Hospital of Philadelphia,
Published by
PR Newswire
04 Dec 16 Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting ArQule, Inc.,
Published by
Business Wire
04 Dec 16 Celgene Corporation, Dana-Farber Cancer Institute and University of Arkansas for Medical Sciences Establish the Myeloma Genome Project Celgene Corporation,
Published by
Business Wire
03 Dec 16 uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B Published by
GlobeNewswire
03 Dec 16 uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B uniQure,
Published by
GlobeNewswire
03 Dec 16 NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors Novo Nordisk A/S,
Published by
GlobeNewswire
03 Dec 16 Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study Novartis International AG,
Published by
GlobeNewswire
03 Dec 16 Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting Seattle Genetics, Inc.,
Published by
Business Wire
03 Dec 16 NovoSeven® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors Published by
GlobeNewswire
03 Dec 16 Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for the Treatment of Multiple Myeloma Published by
GlobeNewswire
03 Dec 16 Novartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II study Published by
GlobeNewswire
03 Dec 16 Sickle Cell Disease Research Shows Progress in Preventing Related Complications and Death American Society of Hematology,
Published by
PR Newswire
03 Dec 16 Pairnomix Presents Systematic Approach To Identifying Approved Drugs That May Be Repurposed For Treatment Of Rare Genetic Diseases Pairnomix, LLC,
Published by
PR Newswire
03 Dec 16 True North Presents Additional Data from an Ongoing Clinical Study Showing Normalization of Hemoglobin Levels with TNT009 in Severely Anemic Cold Agglutinin Disease (CAD) Patients True North Therapeutics,
Published by
Business Wire
03 Dec 16 New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Pfizer Inc.,
Published by
Business Wire
03 Dec 16 CORRECTING and REPLACING Verily Life Sciences Launches Liftware™ Level Device to Help People with Limited Hand and Arm Mobility Eat with Confidence Verily Life Sciences LLC,
Published by
Business Wire
02 Dec 16 Cytokinetics Announces Presentations at the International Symposium on ALS/MND Published by
GlobeNewswire
03 Dec 16 Sovereign Health Examines Insurance and Other Barriers That Affect Addiction Treatment Sovereign Health,
Published by
PR Newswire
03 Dec 16 Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL Juno Therapeutics, Inc.,
Published by
Business Wire
03 Dec 16 Crandon & Crandon Optometry Sponsors the 24th Annual Lawrence Old-Fashioned Christmas Parade Published by
GlobeNewswire
03 Dec 16 Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting Biogen,
Published by
Business Wire
03 Dec 16 Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 Published by
GlobeNewswire
03 Dec 16 City of Hope physicians present new research at 2016 American Society of Hematology meeting City of Hope,
Published by
Business Wire
03 Dec 16 Bellicum Announces Updated Clinical Data from BPX-501 Study in Children with Primary Immune Deficiencies and Hemoglobinopathies Bellicum Pharmaceuticals, Inc.,
Published by
Business Wire
03 Dec 16 Alnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors Alnylam Pharmaceuticals, Inc.,
Published by
Business Wire
03 Dec 16 bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Dependent ß-Thalassemia (TDT) and Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting bluebird bio, Inc.,
Published by
Business Wire
03 Dec 16 After One Dose of Gene Therapy, Hemophilia B Patients Maintain Near-Normal Levels of Clotting Factor The Children's Hospital of Philadelphia,
Published by
PR Newswire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.